3-(Trifluoromethyl)pyrrolidine → HCID 59605329, 화합물

HRID 1923039노트

반응식

HRID 1923039 반응식
Br[CH2:2][C:3]1[N:4]([CH3:28])[C:5]2[C:10]([N:11]=1)=[C:9]([N:12]1[CH2:17][CH2:16][O:15][CH2:14][CH2:13]1)[N:8]=[C:7]([N:18]1[C:22]3[CH:23]=[CH:24][CH:25]=[CH:26][C:21]=3[N:20]=[C:19]1[CH3:27])[N:6]=2.[F:29][C:30]([F:37])([F:36])[CH:31]1[CH2:35][CH2:34][NH:33][CH2:32]1>>[CH3:28][N:4]1[C:3]([CH2:2][N:33]2[CH2:34][CH2:35][CH:31]([C:30]([F:37])([F:36])[F:29])[CH2:32]2)=[N:11][C:10]2[C:5]1=[N:6][C:7]([N:18]1[C:22]3[CH:23]=[CH:24][CH:25]=[CH:26][C:21]=3[N:20]=[C:19]1[CH3:27])=[N:8][C:9]=2[N:12]1[CH2:17][CH2:16][O:15][CH2:14][CH2:13]1

참가 물질

3

반응물 2

HCID 51521593-(Trifluoromethyl)pyrrolidineHCID 596058124-(8-(bromomethyl)-9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-9H-purin-6-yl)morpholine

생성물 1

HCID 59605329HCID 59605329, 화합물

실험 절차

4-(8-(Bromomethyl)-9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-9H-purin-6-yl)morpholine (50 mg) was reacted with 3-(trifluoromethyl)pyrrolidine via General Procedure E to give 19.9 mg of 289 following reverse phase purification. MS (Q1) 501.2 (M)+

후처리

  1. customto give
  2. custom19.9 mg of 289 following reverse phase purification

출처 및 근거

ORD 기록
ord-f0c38859763240c4abf8ed55fe06bd82
출처 데이터셋
uspto-grants-2012_05
특허 번호
US08173650B2

반응 노트

불러오는 중…